

Exclusive agreement for the Philippines

ZymIQ Technology AB has signed an exclusive distribution agreement for its animal health products with the Philippine company Broadchem Philippines BioPharma Corp. ZymIQ's brand Kalzyme® offers a product portfolio designed to meet the most common needs within the Pet Care segment.

Kalzyme®, already an established brand in the Southeast Asian market, is a series of enzyme-based dental, dermatological and otic products with clinically proven effects, developed by scientists and veterinarians. Kalzyme® provides gentle, effective and user-friendly health solutions that promote wellbeing in dogs and cats.

Broadchem, founded in 1989 and accredited by the Philippine FDA, specializes in animal health with a strong focus on innovation, quality, customer satisfaction and solutions that enhance animal wellbeing. The company has built a successful track record through long-term partnerships with multinational enterprises.

The Philippine animal health market is both substantial and rapidly expanding, valued at USD 300–500 million in 2024. Growth is driven by increasing pet ownership, livestock production, and rising demand for improved animal welfare and food safety. Forecasts project the market to exceed USD 1.3 billion by 2030, with a strong annual growth rate of approximately 13%. This positions the country as one of the fastest-growing animal health markets in all of Asia.

Today, the Philippines has the highest rate of pet ownership in Southeast Asia, with 94% of households having pets at home. Combined with the rising purchasing power of the urban middle class and a strong “pet humanization” trend, animal health products have become increasingly important. The premium segment is growing by more than 10% annually, driven by consumers who consider their pets a natural part of the family. This creates a clear market opportunity for innovative and science-based products such as Kalzyme®.

“We are very pleased to add another solid partner in Asia. Broadchem consistently focuses on quality and smart technology, making our enzyme-based platform an excellent fit for their portfolio. During our recent visit, we saw firsthand the impressive development they have undergone in recent years. I look forward to following our partnership and what it will achieve in the Philippines going forward,” says Michael Edelborg Christensen, CEO of ZymIQ.

For more information, please contact:

Michael Edelborg Christensen, CEO

Phone +46 727 144 166

Email: michael.christensen@zymiq.com

About ZymiQ

ZymiQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymiQ Group. Subsidiaries include ZymiQ Biopharma AB, Sweden and ZymiQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymiQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymiQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com

Attachments

[Exclusive agreement for the Philippines](#)